Decitabine CAS 2353-33-5 Purity >99.5% (HPLC) Factory

Decitabine (CAS: 2353-33-5) (trade name Dacogen), or 5-Aza-2'-Deoxycytidine. Chemically, it is a cytidine analog. Decitabine is a hypomethylating agent. Decitabine has been launched for the treatment of myelodysplastic syndromes (MDS). MDS are a set of hematologic disorders affecting the bone marrow that result in ineffective formation and development of blood cells. Furthermore, patients with MDS have a high risk of progressing to acute myeloid leukemia (AML). Traditional treatments include blood transfusions, hematopoietic growth factors, and prophylactic antibiotics, but these measures merely improve the quality of life with questionable effects on disease modification. While stem-cell transplantation is an aggressive, potentially curative approach, the advanced age or the other complicating health issues of most patients preclude them from considering this option. Recent advances in the underlying etiology of MDS, however, have led to the development of a new class of compounds known as ‘‘demethylating agents’’. Decitabine follows the successful introduction of the first DNA methyltransferase inhibitor Azacitidine. It hypomethylates DNA by inhibiting DNA methyltransferase. It functions in a similar manner to Azacitidine, although decitabine can only be incorporated into DNA strands while azacitidine can be incorporated into both DNA and RNA chains. Research reagents: Decitabine is widely used in molecular biology, pharmacology, and other scientific research. Decitabine as a specific DNA methyltransferase inhibitor, reversible DNA methylation process, induced tumor cells to normal cells to differentiate or induce tumor cell apoptosis. Kindly note that the high concentration of Decitabine would play its cytotoxic effect: can inhibit DNA synthesis induced cell death.